研究报告 Research Report 翰森制药 Hansoh Pharma (3692 HK) 1H25 创新药占比超 80%，对外合作收入超预期；管理层上调全年指引 1H25 results review: Innovative Drugs Accounted for 80%+; Collaboration Revenue Beat; Mgmt Raises Full-year Guidance [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$37.66 目标价 HK$44.32 HTI ESG 4.5-4.5-5.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$223.97bn / US$28.67bn 日交易额 (3 个月均值) US$49.32mn 发行股票数目 5,947mn 自由流通股 (%) 19% 1 年股价最高最低值 HK$38.82-HK$16 ...